نتائج البحث

Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide.

• Authors : Brown JT; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.

Subjects: Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/drug therapy ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/pathology ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/mortality

• Source: Cancer medicine [Cancer Med] 2026 Apr; Vol. 15 (4), pp. e71633.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

ANXA2-mediated Phagocytosis Generates AR+ Macrophages to Confer Enzalutamide Resistance in Prostate Cancer.

• Authors : Luo Y; Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.

• Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2026 Apr 16, pp. e75290. Date of Electronic Publication: 2026 Apr 16.Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844

تفاصيل العنوان

BSA-Based Nanoparticles for Dual Loading of Pazopanib and Enzalutamide: Formulation Optimization and In Vitro Evaluation in Breast Cancer Cells.

• Authors : Topal GR; Department of Pharmaceutical Biotechnology, Gulhane Faculty of Pharmacy, University of Health Sciences, Ankara 06010, Türkiye.; Kilic K

• Source: Pharmaceutics [Pharmaceutics] 2026 Apr 13; Vol. 18 (4). Date of Electronic Publication: 2026 Apr 13.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print)

تفاصيل العنوان

A Hybrid Nanosystem for Prostate Cancer Therapy: Codelivery of Enzalutamide and Curcumin via Selenium-Embedded Mesoporous Silica and Chitosan Nanoparticles.

• Authors : Tavakoli Z; Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.; Khajeh K

Subjects: Curcumin*/Curcumin*/Curcumin*/chemistry ; Curcumin*/Curcumin*/Curcumin*/pharmacology ; Silicon Dioxide*/Silicon Dioxide*/Silicon Dioxide*/chemistry

• Source: ChemistryOpen [ChemistryOpen] 2026 Mar; Vol. 15 (3), pp. e202500589.Publisher: Wiley-VCH Verlag Country of Publication: Germany NLM ID: 101594811 Publication Model: Print Cited Medium: Internet ISSN: 2191-1363

تفاصيل العنوان

LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients.

• Authors : Posocco B; Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.; Pasin D

Subjects: Tandem Mass Spectrometry*/Tandem Mass Spectrometry*/Tandem Mass Spectrometry*/methods ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/drug therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/blood

• Source: International journal of molecular sciences [Int J Mol Sci] 2026 Mar 26; Vol. 27 (7). Date of Electronic Publication: 2026 Mar 26.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Integrating Tumor Biology and Host Factors in mCRPC: The Prognostic Value of 'Time to Castration Resistance', Systemic Inflammation, and Comorbidity Burden in Patients Treated with Enzalutamide.

• Authors : Sali S; Department of Medical Oncology, University of Health Sciences, Bursa City Education and Research Hospital, Bursa 16250, Türkiye.; Ulaş A

• Source: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2026 Mar 23; Vol. 16 (6). Date of Electronic Publication: 2026 Mar 23.Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101658402 Publication Model: Electronic Cited Medium: Print ISSN: 2075-4418

تفاصيل العنوان

Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide.

• Authors : Ozkerim U; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.; Kinikoglu O

• Source: Journal of clinical medicine [J Clin Med] 2026 Jan 05; Vol. 15 (1). Date of Electronic Publication: 2026 Jan 05.Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383

تفاصيل العنوان

Correction to "Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide".

• Source: Clinical and translational medicine [Clin Transl Med] 2026 May; Vol. 16 (5), pp. e70690.Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet ISSN: 2001-1326

تفاصيل العنوان

STARD4 suppresses tumorigenesis and attenuates enzalutamide resistance via lipid metabolic reprogramming and AR stabilization in prostate cancer.

• Authors : Zhang Y; Department of Urology, the First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.; Wang X

Subjects: Benzamides*/Benzamides*/Benzamides*/pharmacology ; Receptors, Androgen*/Receptors, Androgen*/Receptors, Androgen*/metabolism ; Receptors, Androgen*/Receptors, Androgen*/Receptors, Androgen*/genetics

• Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2025 Dec 02; Vol. 44 (1), pp. 318. Date of Electronic Publication: 2025 Dec 02.Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966

تفاصيل العنوان

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.

• Authors : Norton N; Department of Cancer Biology, Mayo Clinic Florida, Jacksonville, Florida, USA.; Larson NB

Subjects: Phenylthiohydantoin*/Phenylthiohydantoin*/Phenylthiohydantoin*/analogs & derivatives ; Phenylthiohydantoin*/Phenylthiohydantoin*/Phenylthiohydantoin*/pharmacokinetics ; Phenylthiohydantoin*/Phenylthiohydantoin*/Phenylthiohydantoin*/administration & dosage

• Source: Clinical and translational science [Clin Transl Sci] 2025 Dec; Vol. 18 (12), pp. e70425.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان